Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Maravai LifeSciences Holdings, Inc. (MAR.F)

Compare

3.1000

+0.1800

+(6.16%)

At close: 9:55:02 PM GMT+1

Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against the other AI stocks. In a recent discussion at CNBC’s ‘Squawk on the Street’, NYU professor and AI expert, Gary […]

Insider Monkey 22 hours ago

MRVI
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual repo

GlobeNewswire 3 days ago

MRVI
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

SAN DIEGO, February 24, 2025--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and

Business Wire 4 days ago

MRVI
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

SAN DIEGO, February 04, 2025--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide g

Business Wire 24 days ago

MRVI
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

SAN DIEGO, February 03, 2025--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). This distribution p

Business Wire 25 days ago

MRVI

AVTR
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

SAN DIEGO, January 28, 2025--Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

Business Wire last month

MRVI
Three Top Undervalued Small Caps In US With Insider Buying

Over the last 7 days, the United States market has risen by 3.8%, contributing to a 24% climb over the past year, with earnings expected to grow by 15% annually. In such a dynamic environment, identifying stocks that are potentially undervalued and have insider buying can be key indicators of promising opportunities for investors seeking growth in small-cap companies.

Simply Wall St. last month

MRVI

SDHC

MTW
Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other stocks under $5 with biggest upside potential. On January 20, Bloomberg reported that relief swept through the markets as it became […]

Insider Monkey last month

MRVI
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Announces Earnings Release DateSAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company al

GlobeNewswire last month

MRVI
Maravai Lifesciences initiated with a Neutral at Guggenheim

Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T

TipRanks 2 months ago

MRVI
Exploring December 2024's Undervalued Small Caps With Insider Action In US

Over the last 7 days, the United States market has experienced a 4.0% drop, yet it remains up by 24% over the past year with anticipated earnings growth of 15% per annum in the coming years. In this dynamic environment, identifying promising small-cap stocks with insider activity can offer investors unique opportunities to capitalize on potential market inefficiencies.

Simply Wall St. 2 months ago

MRVI

ONEW

PMTS
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Carl Hull to Retire as Executive ChairmanSAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl H

GlobeNewswire 2 months ago

MRVI

BDX

FTRE
Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US

Over the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities.

Simply Wall St. 3 months ago

ACNB

TLRY

MRVI
Maravai LifeSciences Announces November 2024 Investor Conference Schedule

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in a fireside chat at the Stifel Healthcare Conference in New York, NY. On

GlobeNewswire 3 months ago

MRVI
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price

As you might know, Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) last week released its latest quarterly, and...

Simply Wall St. 3 months ago

MRVI
Maravai Lifesciences price target lowered to $9 from $10 at Baird

Baird analyst Catherine Schulte lowered the firm’s price target on Maravai Lifesciences (MRVI) to $9 from $10 and keeps an Outperform rating on the shares. The firm said they reported 3Q results below expectations, with both segments light versus the firm’s model. In NAP, the company noted soft research/discovery demand, a lack of larger drop-in orders, and a few GMP program timing delays into 2025. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n

TipRanks 3 months ago

MRVI
Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call

Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

MRVI
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 3 months ago

MRVI

PRPH

EVH
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2024.

Motley Fool 3 months ago

MRVI
Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ...

Despite revenue shortfalls and a significant impairment charge, Maravai LifeSciences Holdings Inc (MRVI) continues to innovate with new products and strategic acquisitions.

GuruFocus.com 3 months ago

MRVI

Performance Overview

Return	MAR.F	S&P 500
YTD	-38.00%	+1.24%
1-Year	-57.53%	+17.45%
3-Year	-91.06%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Maravai LifeSciences Holdings, Inc. (MAR.F)

Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development

Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

Three Top Undervalued Small Caps In US With Insider Buying

Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Maravai Lifesciences initiated with a Neutral at Guggenheim

Exploring December 2024's Undervalued Small Caps With Insider Action In US

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price

Maravai Lifesciences price target lowered to $9 from $10 at Baird

Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call

Top Midday Decliners

Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ...

Performance Overview